Trial Profile
Detect EGFR T790M Mutation in ctDNA of Chinese Advanced/Metastatic NSCLC Patients by Cobas, Super-ARMS, Digital PCR and NGS and Evaluate Clinical Outcomes of T790M Mutation Positive Patients Who Had AZD9291 Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Diagnostic use; Therapeutic Use
- Acronyms ADELOS
- Sponsors AstraZeneca
- 16 Nov 2018 Status changed from active, no longer recruiting to completed.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, twenty three of planned two hundred and fifty patients have been enrolled in the study as of January 2017